Evidence map›Paper›PMID 31898192›Full record

ArticleSleep & breathing = Schlaf & Atmung2020

The PAP-NAP one decade later: patient risk factors, indications, and clinically relevant emotional and motivational influences on PAP use.

Victor A Ulibarri, Barry Krakow, Natalia D McIver

Abstract read
PubMed Publisher
In one paragraph

Article in Sleep & breathing = Schlaf & Atmung, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Victor A UlibarriSleep & Human Health Institute, 6739 Academy N.E., Suite 380, Albuquerque, NM, 87109, USA.
Barry KrakowSleep & Human Health Institute, 6739 Academy N.E., Suite 380, Albuquerque, NM, 87109, USA. bkrakow@sleeptreatment.com.
Natalia D McIverSleep & Human Health Institute, 6739 Academy N.E., Suite 380, Albuquerque, NM, 87109, USA.
Sleep and Human Health Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesPositive airway pressure (PAP) noncompliance remains a major barrier in obstructive sleep apnea (OSA) treatment. The PAP-NAP, a daytime PAP "test-drive," has been associated with increased PAP use, but risk factors and indications for the procedure remain unspecified.

methodsA retrospective chart review was conducted on 139 patients who (1) were diagnosed with OSA (n = 116) or upper airway resistance syndrome (UARS) (n = 23); (2) adamantly refused to proceed with either a full-night attended titration or in-home trial of PAP; and (3) elected to proceed with a PAP-NAP instead. Risk factors for PAP rejection (identified on intake) and indications for the PAP-NAP (identified post-diagnostic polysomnography) were confirmed through multiple encounters with sleep center personnel. All patients completed the PAP-NAP, which utilizes an elaborate desensitization program to provide a less challenging introduction and facilitate a gentler adaptation to pressurized air as well as to test advanced PAP modes when subjective or objective expiratory pressure intolerance emerges. Both emotional aversion toward and lack of motivation for PAP therapy were assessed pre- and post-PAP-NAP. PAP use was determined several months post-procedure.

resultsAt intake, most common risk factors for PAP rejection were depression, insomnia, and claustrophobia; most common indications for PAP-NAP were general reluctance, anxiety, and claustrophobia. Procedure averaged 3+ hours [tech coaching, 83 (± 30) min; napping, 107 (± 57) min]. Ninety-nine percent required advanced PAP. Compared to baseline, emotional aversion (p = 0.0001) and motivation (p = 0.0001) significantly improved for the entire sample of which 86% completed full-night titrations and 78% filled PAP prescriptions. At final follow-up, 71% (n = 98) were users and 29% (n = 41) were non-users. Compared to non-users, users showed significantly greater decreases in emotional aversion (p <  0.001; Z = - 6.11) and greater increases in motivation (p <  0.001; Z = - 8.57).

conclusionPAP-NAP was associated with a sizeable proportion of highly reluctant patients proceeding to titrations they initially had rejected, and the majority achieved PAP user status. Improvements in emotional aversion and motivation were associated with increased PAP use. Randomized control trials must assess the experiential component at the core of the PAP-NAP procedure and its efficacy in reversing early PAP rejecters.

Indexed as

Continuous Positive Airway PressureEmotionsFemaleHumansMaleMiddle AgedMotivationPatient ComplianceRetrospective StudiesRisk FactorsSleep Apnea, ObstructiveTreatment OutcomeAdaptive servo-ventilationAuto-bilevelDesensitizationImageryPAP adherencePAP failure risksPAP-NAP indicationsPositive airway pressure therapySleep-disordered breathingSomatosensory amplification

Identifiers

PMID31898192
OpenAlexW2998102297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.